News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: VARTA AG: VARTA AG announces approval of the restructuring plan according to StaRUG by the majority of the groups
VARTA AG announces approval of restructuring plan according to StaRUG by majority of shareholder groups, detailing financial restructuring and new equity raise -
-
COMMUNIQUÉ DE PRESSE
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
TuHURA Biosciences, Inc. provides a business update on its innovative cancer immunotherapy technologies, including IFx-2.0 Phase 3 trial for Merkel Cell Carcinoma, potential KVA12123 acquisition, and key management appointments -
-
